Autologous stem cell transplantation in patients who object to a blood transfusion: contribution of new pharmacological haematopoiesis support. (abre una nueva ventana)

Al-Nawakil C, Quarre MC, Heshmati F, Deau B, Park S, Dreyfus F, Bouscary D, Tamburini J.

Fuente‎: Br J Haematol 2013;161(5):738-40.

Indexado en‎: PubMed 23480574

DOI‎: 10.1111/bjh.12284

https://www.ncbi.nlm.nih.gov/pubmed/23480574 (abre una nueva ventana)

A multicenter study of romiplostim for chemotherapy-induced thrombocytopenia in solid tumors and hematologic malignancies. (abre una nueva ventana)

Al-Samkari H, Parnes AD, Goodarzi K, Weitzman JI, Connors JM, Kuter DJ

Fuente‎: Haematologica 2021;106(4):1148-57.

Indexado en‎: PubMed 32499239

DOI‎: 10.3324/haematol.2020.251900

https://www.ncbi.nlm.nih.gov/pubmed/32499239 (abre una nueva ventana)

The effect of interleukin 11 on thrombocytopenia associated with tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia. (abre una nueva ventana)

Aribi A, Kantarjian H, Koller C, Thomas D, Faderl S, Garcia-Manero G, Cortes J.

Fuente‎: Cancer 2008;113(6):1338-43.

Indexado en‎: PubMed 18629842

DOI‎: 10.1002/cncr.23718

https://www.ncbi.nlm.nih.gov/pubmed/18629842 (abre una nueva ventana)

Romiplostim efficacy in an acute myeloid leukemia patient with transfusion refractory thrombocytopenia. (abre una nueva ventana)

Berthelot-Richer M, Boilard B, Morin A, Bolduc B, Beauregard P, Kotb R.

Fuente‎: Transfusion 2012;52(4):739-41.

Indexado en‎: PubMed 22082044

DOI‎: 10.1111/j.1537-2995.2011.03382.x

https://www.ncbi.nlm.nih.gov/pubmed/22082044 (abre una nueva ventana)

The role of interleukin-11 to prevent chemotherapy-induced thrombocytopenia in patients with solid tumors, lymphoma, acute myeloid leukemia and bone marrow failure syndromes. (abre una nueva ventana)

Bhatia M, Davenport V, Cairo MS.

Fuente‎: Leuk Lymphoma 2007;48(1):9-15.

Indexado en‎: PubMed 17325843

DOI‎: 10.1080/10428190600909115

https://www.ncbi.nlm.nih.gov/pubmed/17325843 (abre una nueva ventana)

Results of a phase I dose escalation study of eltrombopag in patients with advanced soft tissue sarcoma receiving doxorubicin and ifosfamide. (abre una nueva ventana)

Chawla SP, Staddon A, Hendifar A, Messam CA, Patwardhan R, Kamel YM.

Fuente‎: BMC Cancer 2013;13:121.

Indexado en‎: PubMed 23497336

DOI‎: 10.1186/1471-2407-13-121

https://www.ncbi.nlm.nih.gov/pubmed/23497336 (abre una nueva ventana)

Efficacy of romiplostim in the treatment of chemotherapy induced thrombocytopenia (CIT) in a patient with mantle cell lymphoma. (abre una nueva ventana)

Demeter J, Istenes I, Fodor A, Paksi M, Dombi P, Valasinyószki E, Csomor J, Matolcsy A, Nagy ZG.

Fuente‎: Pathol Oncol Res 2011;17(1):141-3.

Indexado en‎: PubMed 20628840

DOI‎: 10.1007/s12253-010-9276-4

https://www.ncbi.nlm.nih.gov/pubmed/20628840 (abre una nueva ventana)

Eltrombopag for radiation-induced thrombocytopenia in a glioblastoma patient. (abre una nueva ventana)

Duic JP, Grewal J, McConie K, Staszewski H, Haas J, Kesari S.

Fuente‎: J Neurooncol 2012;106(2):427-9.

Indexado en‎: PubMed 21833801

DOI‎: 10.1007/s11060-011-0675-5

https://www.ncbi.nlm.nih.gov/pubmed/21833801 (abre una nueva ventana)

Recombinant human interleukin 11 and bacterial infection in patients with haematological malignant disease undergoing chemotherapy: a double-blind placebo-controlled randomised trial. (abre una nueva ventana)

Ellis M, Zwaan F, Hedström U, Poynton C, Kristensen J, Jumaa P, Wassell J, al-Ramadi B.

Fuente‎: Lancet 2003;361(9354):275-80.

Indexado en‎: PubMed 12559860

https://www.ncbi.nlm.nih.gov/pubmed/12559860 (abre una nueva ventana)

Autologous stem-cell transplantation without hematopoietic support for the treatment of hematologic malignancies in Jehovah's Witnesses. (abre una nueva ventana)

Ford PA, Grant SJ, Mick R, Keck G.

Fuente‎: J Clin Oncol 2015;33(15):1674-9.

Indexado en‎: PubMed 25870085

DOI‎: 10.1200/JCO.2014.57.9912

https://www.ncbi.nlm.nih.gov/pubmed/25870085 (abre una nueva ventana)

Effect of avatrombopag in the management of severe and refractory chemotherapy-induced thrombocytopenia (CIT) in patients with solid tumors. (abre una nueva ventana)

Gao Y, Liu Q, Shen Y, Li Y, Shao K, Ye B, Shen Y, Zhou Y, Wu D

Fuente‎: Platelets. 2022 3;33(7):1024-1030.

Indexado en‎: PubMed 35040375

DOI‎: 10.1080/09537104.2022.2026910

https://pubmed.ncbi.nlm.nih.gov/35040375/ (abre una nueva ventana)

Results of a randomized, double-blind study of romiplostim versus placebo in patients with low/intermediate-1-risk myelodysplastic syndrome and thrombocytopenia. (abre una nueva ventana)

Giagounidis A, Mufti GJ, Fenaux P, Sekeres MA, Szer J, Platzbecker U, Kuendgen A, Gaidano G, Wiktor-Jedrzejczak W, Hu K, Woodard P, Yang AS, Kantarjian HM.

Fuente‎: Cancer 2014;120(12):1838-46.

Indexado en‎: PubMed 24706489

DOI‎: 10.1002/cncr.28663

https://www.ncbi.nlm.nih.gov/pubmed/24706489 (abre una nueva ventana)

A randomized controlled trial of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving decitabine. (abre una nueva ventana)

Greenberg PL, Garcia-Manero G, Moore M, Damon L, Roboz G, Hu K, Yang AS, Franklin J.

Fuente‎: Leuk Lymphoma 2013;54(2):321-8.

Indexado en‎: PubMed 22906162

DOI‎: 10.3109/10428194.2012.713477

https://www.ncbi.nlm.nih.gov/pubmed/22906162 (abre una nueva ventana)

Thrombopoietin-receptor agonists in haematological disorders: the Danish experience. (abre una nueva ventana)

Gudbrandsdottir S, Frederiksen H, Hasselbalch H.

Fuente‎: Platelets 2012;23(6):423-9.

Indexado en‎: PubMed 22185370

DOI‎: 10.3109/09537104.2011.634931

https://www.ncbi.nlm.nih.gov/pubmed/22185370 (abre una nueva ventana)

Recombinant human thrombopoietin promotes platelet engraftment after haploidentical hematopoietic stem cell transplantation: a prospective randomized controlled trial. (abre una nueva ventana)

Han TT, Xu LP, Liu DH, Liu KY, Wang FR, Wang Y, Yan CH, Chen YH, Sun YQ, Ji Y, Wang JZ, Zhang XH, Huang XJ.

Fuente‎: Ann Hematol 2015;94(1):117-28.

Indexado en‎: PubMed 25069650

DOI‎: 10.1007/s00277-014-2158-1

https://www.ncbi.nlm.nih.gov/pubmed/25069650 (abre una nueva ventana)

The non-peptide thrombopoietin receptor agonist eltrombopag stimulates megakaryopoiesis in bone marrow cells from patients with relapsed multiple myeloma. (abre una nueva ventana)

Jeong JY, Levine MS, Abayasekara N, Berliner N, Laubach J, Vanasse GJ.

Fuente‎: J Hematol Oncol 2015;8:37.

Indexado en‎: PubMed 25886818

DOI‎: 10.1186/s13045-015-0136-2

https://www.ncbi.nlm.nih.gov/pubmed/25886818 (abre una nueva ventana)

Safety and efficacy of romiplostim in patients with lower-risk myelodysplastic syndrome and thrombocytopenia. (abre una nueva ventana)

Kantarjian H, Fenaux P, Sekeres MA, Becker PS, Boruchov A, Bowen D, Hellstrom-Lindberg E, Larson RA, Lyons RM, Muus P, Shammo J, Siegel R, Hu K, Franklin J, Berger DP.

Fuente‎: J Clin Oncol 2010;28(3):437-44.

Indexado en‎: PubMed 20008626

DOI‎: 10.1200/JCO.2009.24.7999

https://www.ncbi.nlm.nih.gov/pubmed/20008626 (abre una nueva ventana)

The use of simple patient blood management strategies as an alternative to platelet and red cell transfusion in autologous stem cell transplant. (abre una nueva ventana)

Locantore-Ford P, Grant SJ, Keck G.

Fuente‎: Blood 2013;122(21):2140.

https://www.bloodjournal.org/content/122/21/2140 (abre una nueva ventana)

The effect of recombinant human erythropoietin on platelet counts is strongly modulated by the adequacy of iron supply. (abre una nueva ventana)

Loo M, Beguin Y.

Fuente‎: Blood 1999;93(10):3286-93.

Indexado en‎: PubMed 10233880

https://www.ncbi.nlm.nih.gov/pubmed/10233880 (abre una nueva ventana)

A single center experience with romiplostim for the management of chemotherapy-induced thrombocytopenia. (abre una nueva ventana)

Miao J, Leblebjian H, Scullion B, Parnes A

Fuente‎: Am J Hematol 2018;93(4):E86-E88.

Indexado en‎: PubMed 29274130

DOI‎: 10.1002/ajh.25022

https://www.ncbi.nlm.nih.gov/pubmed/29274130 (abre una nueva ventana)

Pharmacological therapies to minimise platelet transfusion. (abre una nueva ventana)

Norfolk DR, Seghatchian J.

Fuente‎: Transfus Sci 2000;22(3):149-53.

Indexado en‎: PubMed 10831916

https://www.ncbi.nlm.nih.gov/pubmed/10831916 (abre una nueva ventana)

Romiplostim for management of chemotherapy-induced thrombocytopenia. (abre una nueva ventana)

Parameswaran R, Lunning M, Mantha S, Devlin S, Hamilton A, Schwartz G, Soff G.

Fuente‎: Support Care Cancer 2014;22(5):1217-22.

Indexado en‎: PubMed 24414994

DOI‎: 10.1007/s00520-013-2074-2

https://www.ncbi.nlm.nih.gov/pubmed/24414994 (abre una nueva ventana)

Eltrombopag for the treatment of thrombocytopenia in patients with malignant and non-malignant hematologic disorders. (abre una nueva ventana)

Pathak S, Roth M, Verma A, Steidl U.

Fuente‎: Expert Opin Drug Metab Toxicol 2013;9(12):1667-75.

Indexado en‎: PubMed 24215532

DOI‎: 10.1517/17425255.2013.858119

https://www.ncbi.nlm.nih.gov/pubmed/24215532 (abre una nueva ventana)

High-dose chemotherapy without transfusion for Philadelphia chromosome negative B-cell acute lymphoblastic leukemia in two Jehovah's Witnesses patients: a feasible option in the age of hematopoietic growth factors. (abre una nueva ventana)

Perol L, Grignano E, Contejean A, Gastaud L, Legoff M, Franchi P, Deau-Fischer B, Willems L, Bouscary D, Tamburini J

Fuente‎: Leuk Lymphoma. 2019;60(9):2324-7.

Indexado en‎: PubMed 30773115

DOI‎: 10.1080/10428194.2019.1577414

https://www.ncbi.nlm.nih.gov/pubmed/30773115 (abre una nueva ventana)

Safety and tolerability of eltrombopag versus placebo for treatment of thrombocytopenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: a multicentre, randomised, placebo-controlled, double-blind, phase 1/2 trial. (abre una nueva ventana)

Platzbecker U, Wong RS, Verma A, Abboud C, Araujo S, Chiou TJ, Feigert J, Yeh SP, Götze K, Gorin NC, Greenberg P, Kambhampati S, Kim YJ, Lee JH, Lyons R, Ruggeri M, Santini V, Cheng G, Jang JH, Chen CY, Johnson B, Bennett J, Mannino F, Kamel YM, Stone N, Dougherty S, Chan G, Giagounidis A.

Fuente‎: Lancet Haematol 2015;2(10):e417-26.

Indexado en‎: PubMed 26686043

https://www.ncbi.nlm.nih.gov/pubmed/26686043 (abre una nueva ventana)

Romiplostim for delayed platelet recovery and secondary thrombocytopenia following allogeneic stem cell transplantation. (abre una nueva ventana)

Poon LM, Di Stasi A, Popat U, Champlin RE, Ciurea SO.

Fuente‎: Am J Blood Res 2013;3(3):260-4.

Indexado en‎: PubMed 23997988

https://www.ncbi.nlm.nih.gov/pubmed/23997988 (abre una nueva ventana)

Safety and efficacy of eltrombopag in post-hematopoietic stem cell transplantation (HSCT) thrombocytopenia. (abre una nueva ventana)

Raut SS, Shah SA, Sharanangat VV, Shah KM, Patel KA, Anand AS, Talati SS, Panchal HP, Patel AA, Parikh SK, Shukla SN.

Fuente‎: Indian J Hematol Blood Transfus 2015;31(4):413-5.

Indexado en‎: PubMed 26306064

DOI‎: 10.1007/s12288-014-0491-0

https://www.ncbi.nlm.nih.gov/pubmed/26306064 (abre una nueva ventana)

Identifying drugs that cause acute thrombocytopenia: an analysis using 3 distinct methods. (abre una nueva ventana)

Reese JA, Li X, Hauben M, Aster RH, Bougie DW, Curtis BR, George JN, Vesely SK.

Fuente‎: Blood 2010;116(12):2127-33.

Indexado en‎: PubMed 20530792

DOI‎: 10.1182/blood-2010-03-276691

https://www.ncbi.nlm.nih.gov/pubmed/20530792 (abre una nueva ventana)

Eltrombopag inhibits the proliferation of leukemia cells via reduction of intracellular iron and induction of differentiation. (abre una nueva ventana)

Roth M, Will B, Simkin G, Narayanagari S, Barreyro L, Bartholdy B, Tamari R, Mitsiades CS, Verma A, Steidl U.

Fuente‎: Blood 2012;120(2):386-94.

Indexado en‎: PubMed 22627766

DOI‎: 10.1182/blood-2011-12-399667

https://www.ncbi.nlm.nih.gov/pubmed/22627766 (abre una nueva ventana)

Subcutaneous or intravenous administration of romiplostim in thrombocytopenic patients with lower risk myelodysplastic syndromes. (abre una nueva ventana)

Sekeres MA, Kantarjian H, Fenaux P, Becker P, Boruchov A, Guerci-Bresler A, Hu K, Franklin J, Wang YM, Berger D.

Fuente‎: Cancer 2011;117(5):992-1000.

Indexado en‎: PubMed 20945323

DOI‎: 10.1002/cncr.25545

https://www.ncbi.nlm.nih.gov/pubmed/20945323 (abre una nueva ventana)

Romiplostim treatment of chemotherapy-induced thrombocytopenia. (abre una nueva ventana)

Soff GA, Miao Y, Bendheim G, Batista J, Mones JV, Parameswaran R, Wilkins CR, Devlin SM, Abou-Alfa GK, Cercek A, Kemeny NE, Sarasohn DM, Mantha S

Fuente‎: J Clin Oncol 2019;37(31):2892-8.

Indexado en‎: PubMed 31545663

DOI‎: 10.1200/JCO.18.01931

https://www.ncbi.nlm.nih.gov/pubmed/31545663 (abre una nueva ventana)

Effects of erythropoietin on platelet reactivity and thrombopoiesis in humans. (abre una nueva ventana)

Stohlawetz PJ, Dzirlo L, Hergovich N, Lackner E, Mensik C, Eichler HG, Kabrna E, Geissler K, Jilma B.

Fuente‎: Blood 2000;95(9):2983-9.

Indexado en‎: PubMed 10779449

https://www.ncbi.nlm.nih.gov/pubmed/10779449 (abre una nueva ventana)

A pilot phase I dose finding safety study of the thrombopoietin-receptor agonist, eltrombopag, in patients with myelodysplastic syndrome treated with azacitidine. (abre una nueva ventana)

Svensson T, Chowdhury O, Garelius H, Lorenz F, Saft L, Jacobsen SE, Hellström-Lindberg E, Cherif H.

Fuente‎: Eur J Haematol 2014;93(5):439-45.

Indexado en‎: PubMed 24853277

DOI‎: 10.1111/ejh.12383

https://www.ncbi.nlm.nih.gov/pubmed/24853277 (abre una nueva ventana)

Eltrombopag for treatment of thrombocytopenia after allogeneic hematopoietic cell transplantation. (abre una nueva ventana)

Tanaka T, Inamoto Y, Yamashita T, Fuji S, Okinaka K, Kurosawa S, Kim SW, Tanosaki R, Fukuda T.

Fuente‎: Biol Blood Marrow Transplant 2016;22(5):919-24.

Indexado en‎: PubMed 26785333

DOI‎: 10.1016/j.bbmt.2016.01.018

https://www.ncbi.nlm.nih.gov/pubmed/26785333 (abre una nueva ventana)

Low-dose interleukin-11 in patients with bone marrow failure: update of the M. D. Anderson Cancer Center experience. (abre una nueva ventana)

Tsimberidou AM, Giles FJ, Khouri I, Bueso-Ramos C, Pilat S, Thomas DA, Cortes J, Kurzrock R.

Fuente‎: Ann Oncol 2005;16(1):139-45.

Indexado en‎: PubMed 15598951

DOI‎: 10.1093/annonc/mdi007

https://www.ncbi.nlm.nih.gov/pubmed/15598951 (abre una nueva ventana)

A randomized, double-blind, placebo-controlled phase 2 study evaluating the efficacy and safety of romiplostim treatment of patients with low or intermediate-1 risk myelodysplastic syndrome receiving lenalidomide. (abre una nueva ventana)

Wang ES, Lyons RM, Larson RA, Gandhi S, Liu D, Matei C, Scott B, Hu K, Yang AS.

Fuente‎: J Hematol Oncol 2012;5:71.

Indexado en‎: PubMed 23190430

DOI‎: 10.1186/1756-8722-5-71

https://www.ncbi.nlm.nih.gov/pubmed/23190430 (abre una nueva ventana)

Romiplostim for chemotherapy-induced thrombocytopenia: efficacy and safety of extended use. (abre una nueva ventana)

Wilkins CR, Ortiz J, Gilbert LJ, Yin S, Mones JV, Parameswaran R, Mantha S, Soff GA

Fuente‎: Res Pract Thromb Haemost. 2022;6(3):e12701.

Indexado en‎: PubMed 35582038

DOI‎: 10.1002/rth2.12701

https://pubmed.ncbi.nlm.nih.gov/35582038/ (abre una nueva ventana)

Effect of the nonpeptide thrombopoietin receptor agonist eltrombopag on bone marrow cells from patients with acute myeloid leukemia and myelodysplastic syndrome. (abre una nueva ventana)

Will B, Kawahara M, Luciano JP, Bruns I, Parekh S, Erickson-Miller CL, Aivado MA, Verma A, Steidl U.

Fuente‎: Blood 2009;114(18):3899-908.

Indexado en‎: PubMed 19710504

DOI‎: 10.1182/blood-2009-04-219493

https://www.ncbi.nlm.nih.gov/pubmed/19710504 (abre una nueva ventana)